Abstract
Arterial thrombosis (manifested as myocardial infarction, ischaemic stroke, or peripheral occlusive artery disease) and venous thrombosis (main clinical presentations include deep vein thrombosis and pulmonary embolism) represent major health problems that are associated with high rates of morbidity and mortality, particularly in Western societies. Several lines of evidence point to a role of novel hemostatic genetic risk factors in influencing thrombotic risk. In fact, it is becoming increasingly clear that the analysis of genetic risk factors and plasmatic factors, together with private life style and environmental factors may contribute significantly to our understanding of the genetic predisposition to vascular thrombosis. The most significant breakthrough was the confirmation of the notion that inherited hypercoagulable conditions are present in a large proportion of patients with venous thromboembolism. These include mutations in the genes encoding antithrombin, protein C, protein S, factor V, and prothrombin. Moreover, plasmatic risk indicators like hyperhomocysteinemia and elevated concentrations of factors II, VIII, IX, XI and fibrinogen have also been documented. Plasma levels of proteins of the hemostatic system also predict the onset and outcome of arterial thrombosis. Several studies examined the relationship between genetic markers of the hemostatic system (platelet receptors, endothelial receptors, anticoagulant proteins, coagulation factors and proteins of the fibrinolytic system) and arterial disease. The results from these studies are frequently conflicting and often are not concordant with plasmatic studies. Therefore, large prospective studies remain needed in order to evaluate the significance of hemostatic plasma levels and gene variations in arterial thrombotic diseases.
Keywords: Genetic Variations, Hemostatic System, Risk Factors, Arterial Thrombotic Disease, platelet, fibrinolytic system
Current Genomics
Title: Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Volume: 4 Issue: 4
Author(s): R. F. Franco, M. D. Trip and P. H. Reitsma
Affiliation:
Keywords: Genetic Variations, Hemostatic System, Risk Factors, Arterial Thrombotic Disease, platelet, fibrinolytic system
Abstract: Arterial thrombosis (manifested as myocardial infarction, ischaemic stroke, or peripheral occlusive artery disease) and venous thrombosis (main clinical presentations include deep vein thrombosis and pulmonary embolism) represent major health problems that are associated with high rates of morbidity and mortality, particularly in Western societies. Several lines of evidence point to a role of novel hemostatic genetic risk factors in influencing thrombotic risk. In fact, it is becoming increasingly clear that the analysis of genetic risk factors and plasmatic factors, together with private life style and environmental factors may contribute significantly to our understanding of the genetic predisposition to vascular thrombosis. The most significant breakthrough was the confirmation of the notion that inherited hypercoagulable conditions are present in a large proportion of patients with venous thromboembolism. These include mutations in the genes encoding antithrombin, protein C, protein S, factor V, and prothrombin. Moreover, plasmatic risk indicators like hyperhomocysteinemia and elevated concentrations of factors II, VIII, IX, XI and fibrinogen have also been documented. Plasma levels of proteins of the hemostatic system also predict the onset and outcome of arterial thrombosis. Several studies examined the relationship between genetic markers of the hemostatic system (platelet receptors, endothelial receptors, anticoagulant proteins, coagulation factors and proteins of the fibrinolytic system) and arterial disease. The results from these studies are frequently conflicting and often are not concordant with plasmatic studies. Therefore, large prospective studies remain needed in order to evaluate the significance of hemostatic plasma levels and gene variations in arterial thrombotic diseases.
Export Options
About this article
Cite this article as:
Franco F. R., Trip D. M. and Reitsma H. P., Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease, Current Genomics 2003; 4 (4) . https://dx.doi.org/10.2174/1389202033490349
DOI https://dx.doi.org/10.2174/1389202033490349 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Sex Differences in Alcohol Use Disorder
Current Medicinal Chemistry Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology Biomarkers Associated with Atrial Fibrosis and Remodeling
Current Medicinal Chemistry Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation Injury from the Anthracycline Antibiotics
Current Pharmaceutical Biotechnology Subject Index to Volume 2
Current Vascular Pharmacology Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Beta-Blockers (Carvedilol) in Children with Systemic Ventricle Systolic Dysfunction - Systematic Review and Meta-Analysis
Reviews on Recent Clinical Trials Cardiomyocyte-Specific TβR2 Knockout Mice are More Susceptible to Cardiac Hypertrophy Induced by Adrenergic Agonist Stimulation
Current Molecular Medicine Cardiotonic Steroids, Hypertension and Cardiovascular Disease
Current Hypertension Reviews Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Cardiac Imaging in Heart Failure with Comorbidities
Current Cardiology Reviews Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry Cardiovascular Magnetic Resonance T2-weighted Imaging of Myocardial Edema in Acute Myocardial Infarction
Recent Patents on Cardiovascular Drug Discovery Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
Current Cardiology Reviews Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias
Current Cardiology Reviews Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews